Catalent Inc. (CTLT): Price and Financial Metrics
GET POWR RATINGS... FREE!
CTLT POWR Grades
- Value is the dimension where CTLT ranks best; there it ranks ahead of 34.54% of US stocks.
- The strongest trend for CTLT is in Growth, which has been heading down over the past 177 days.
- CTLT's current lowest rank is in the Momentum metric (where it is better than 19.86% of US stocks).
CTLT Stock Summary
- CTLT has a higher market value than 85.73% of US stocks; more precisely, its current market capitalization is $11,574,415,342.
- The price/operating cash flow metric for CATALENT INC is higher than 87.62% of stocks in our set with a positive cash flow.
- The volatility of CATALENT INC's share price is greater than that of 87.34% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to CATALENT INC, a group of peers worth examining would be RE, PKG, WSC, LDOS, and GTES.
- CTLT's SEC filings can be seen here. And to visit CATALENT INC's official web site, go to www.catalent.com.
CTLT Valuation Summary
- CTLT's price/earnings ratio is 28.3; this is 21.98% higher than that of the median Healthcare stock.
- CTLT's price/sales ratio has moved up 1.1 over the prior 105 months.
Below are key valuation metrics over time for CTLT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CTLT | 2023-03-24 | 2.4 | 2.4 | 28.3 | 24.7 |
| CTLT | 2023-03-23 | 2.4 | 2.3 | 27.6 | 24.2 |
| CTLT | 2023-03-22 | 2.4 | 2.4 | 28.5 | 24.8 |
| CTLT | 2023-03-21 | 2.5 | 2.4 | 29.4 | 25.4 |
| CTLT | 2023-03-20 | 2.5 | 2.5 | 29.5 | 25.4 |
| CTLT | 2023-03-17 | 2.5 | 2.5 | 29.5 | 25.5 |
CTLT Growth Metrics
- Its year over year revenue growth rate is now at 25.17%.
- Its 4 year net cashflow from operations growth rate is now at 52.44%.
- Its 5 year net cashflow from operations growth rate is now at 52.44%.
The table below shows CTLT's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-12-31 | 4,757 | 329 | 409 |
| 2022-09-30 | 4,825 | 184 | 421 |
| 2022-06-30 | 4,828 | 439 | 503 |
| 2022-03-31 | 4,703.2 | 504.3 | 486.9 |
| 2021-12-31 | 4,483.5 | 441.3 | 563 |
| 2021-09-30 | 4,177.3 | 446.3 | 546.6 |
CTLT's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CTLT has a Quality Grade of C, ranking ahead of 31.5% of graded US stocks.
- CTLT's asset turnover comes in at 0.461 -- ranking 93rd of 682 Pharmaceutical Products stocks.
- INSM, SPPI, and HSKA are the stocks whose asset turnover ratios are most correlated with CTLT.
The table below shows CTLT's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.461 | 0.342 | 0.125 |
| 2021-06-30 | 0.469 | 0.338 | 0.131 |
| 2021-03-31 | 0.459 | 0.332 | 0.129 |
| 2020-12-31 | 0.447 | 0.323 | 0.086 |
| 2020-09-30 | 0.451 | 0.322 | 0.082 |
| 2020-06-30 | 0.456 | 0.318 | 0.073 |
CTLT Stock Price Chart Interactive Chart >
CTLT Price/Volume Stats
| Current price | $67.79 | 52-week high | $115.33 |
| Prev. close | $66.91 | 52-week low | $40.69 |
| Day low | $67.17 | Volume | 9,389 |
| Day high | $68.08 | Avg. volume | 2,356,720 |
| 50-day MA | $64.84 | Dividend yield | N/A |
| 200-day MA | $74.11 | Market Cap | 12.21B |
Catalent Inc. (CTLT) Company Bio
Catalent, Inc. (Catalent Pharma Solutions) is a multinational corporation headquartered in Somerset, New Jersey. It is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. It employs more than 14,000 people, including approximately 2,400 scientists and technicians. In fiscal year 2020, it generated over $3 billion in annual revenue. (Source:Wikipedia)
Latest CTLT News From Around the Web
Below are the latest news stories about CATALENT INC that investors may wish to consider to help them evaluate CTLT as an investment opportunity.
Catalent (CTLT) Declined on Lowered GuidanceAristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the fund posted a return of 6.92% net of fees compared to a 7.56% return for the S&P 500 Index. The fund’s underperformance in the quarter […] |
Catalent (NYSE:CTLT) sheds 4.0% this week, as yearly returns fall more in line with earnings growthStock pickers are generally looking for stocks that will outperform the broader market. And the truth is, you can make... |
2 Clinical Research Stocks That Could Grow by More Than 10% This Year, and 1 to WatchAccording to the National Center for Advancing Translational Sciences, the average period from therapy discovery to Food and Drug Administration (FDA) approval is 14 years and costs $1 billion. Clinical research organizations (CROs) and contract development and manufacturing organizations (CDMOs) are growing because the increasing price of developing, testing, manufacturing, and marketing therapies has made it more important that pharmaceutical companies speed the process along with fewer failures. Rather than doing all the clinical trial work or manufacturing work in-house, more healthcare companies are turning to CROs and CDMOs to reduce overhead and expedite bringing therapies to market. |
Catalent (CTLT) Inks Deal for Nasal Spray for Opioid OverdosesCatalent's (CTLT) latest commercial supply agreement is expected to combat the opioid epidemic by making OTC naloxone more widely and easily accessible. |
Should You Exit Catalent (CTLT)?TimesSquare Capital Management, an equity investment management company, released its “U.S. Small/Mid Cap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here. In the fourth quarter, the strategy outperformed the Russell 2500 Growth Index and returned 6.03% (gross), and the index return was 4.72%. For the full year, the strategy return […] |
CTLT Price Returns
| 1-mo | -0.63% |
| 3-mo | 50.61% |
| 6-mo | -6.32% |
| 1-year | -38.83% |
| 3-year | 34.37% |
| 5-year | 65.10% |
| YTD | 50.61% |
| 2022 | -64.84% |
| 2021 | 23.02% |
| 2020 | 84.85% |
| 2019 | 80.56% |
| 2018 | -24.10% |
Continue Researching CTLT
Here are a few links from around the web to help you further your research on Catalent Inc's stock as an investment opportunity:Catalent Inc (CTLT) Stock Price | Nasdaq
Catalent Inc (CTLT) Stock Quote, History and News - Yahoo Finance
Catalent Inc (CTLT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...